NASDAQ:RSLS • US76090R3093
The current stock price of RSLS is 3.92 USD. In the past month the price increased by 37.54%. In the past year, price decreased by -98.49%.
ChartMill assigns a technical rating of 1 / 10 to RSLS. When comparing the yearly performance of all stocks, RSLS is a bad performer in the overall market: 99.02% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to RSLS. The financial health of RSLS is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months RSLS reported a non-GAAP Earnings per Share(EPS) of -212.11. The EPS increased by 93.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.42% | ||
| ROE | -281.54% | ||
| Debt/Equity | 0 |
For the next year, analysts expect an EPS growth of 20% and a revenue growth 20% for RSLS
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.62 | 195.936B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.53 | 172.536B | ||
| SYK | STRYKER CORP | 24.21 | 139.985B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.34 | 110.826B | ||
| IDXX | IDEXX LABORATORIES INC | 42.48 | 50.254B | ||
| BDX | BECTON DICKINSON AND CO | 11.16 | 50.113B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.52 | 44.027B | ||
| RMD | RESMED INC | 20.57 | 36.792B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16 | 36.615B | ||
| DXCM | DEXCOM INC | 27.73 | 27.309B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 17 full-time employees. The company went IPO on 2016-10-06. The firm offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The Diabetes Bloc-Stim Neuromodulation system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0 FLEX, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
RESHAPE LIFESCIENCES INC
1001 Calle Amanecer
San Clemente CALIFORNIA 92673 US
CEO: Andrew Rasdal
Employees: 17
Phone: 19494296680
ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 17 full-time employees. The company went IPO on 2016-10-06. The firm offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The Diabetes Bloc-Stim Neuromodulation system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0 FLEX, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
The current stock price of RSLS is 3.92 USD. The price increased by 22.5% in the last trading session.
RSLS does not pay a dividend.
RSLS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
RSLS stock is listed on the Nasdaq exchange.